Profile data is unavailable for this security.
About the company
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Company’s segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.
- Revenue in INR (TTM)39.99bn
- Net income in INR13.88bn
- Incorporated1981
- Employees3.98k
- LocationNatco Pharma LtdNatco House, Road No 2, Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 023547532
- Fax+91 4 023545298
- Websitehttp://www.natcopharma.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 137.25bn | 3.55k | 35.05 | 5.31 | 23.68 | 6.83 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Sanofi India Ltd | 28.47bn | 5.49bn | 157.50bn | 2.17k | 28.68 | -- | 26.74 | 5.53 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Concord Biotech Ltd | 10.17bn | 3.08bn | 160.12bn | 1.38k | 51.99 | 10.49 | 44.27 | 15.74 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 161.46bn | 947.00 | 99.98 | 22.68 | 91.51 | 12.46 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 174.59bn | 14.59k | 28.34 | 3.62 | 19.63 | 2.80 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | -- | 9.77 | 10.82 | 12.94 | 14.38 | 72.46 | 67.67 | 9.90 | 12.58 | 0.9863 | 11.76 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 183.07bn | 1.17k | 60.89 | 8.93 | 51.61 | 17.41 | 11.81 | 11.81 | 41.36 | 80.56 | 0.4983 | 1.64 | 8.60 | -- | 14.23 | 23.17 | 15.19 | 26.20 | 57.59 | 58.56 | 28.56 | 33.21 | 9.65 | 66.88 | 0.0307 | -- | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Enterprises Ltd | 80.27bn | -16.84bn | 198.01bn | 12.22k | -- | 0.7429 | -- | 2.47 | -76.51 | -76.51 | 345.53 | 1,187.94 | 0.0965 | -- | 497.33 | -- | -2.02 | 2.57 | -2.05 | 3.16 | 45.17 | 81.98 | -20.97 | 21.59 | -- | -0.0035 | 0.6686 | 26.39 | -3.80 | -7.55 | -116.89 | -- | 12.91 | -18.22 |
| Piramal Pharma Ltd | 81.71bn | 178.20m | 208.50bn | 6.30k | 2,631.00 | 2.64 | 27.49 | 2.55 | 0.06 | 0.06 | 65.09 | 59.80 | 0.5478 | 1.53 | 4.15 | -- | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Natco Pharma Ltd. | 39.99bn | 13.88bn | 216.83bn | 3.98k | 15.66 | 3.70 | 13.77 | 5.42 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Pfizer Ltd | 21.93bn | 5.51bn | 220.92bn | 1.70k | 40.07 | 6.14 | 36.00 | 10.07 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 234.47bn | 5.75k | 146.43 | 5.70 | 42.42 | 4.65 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Syngene International Ltd | 34.89bn | 5.10bn | 283.73bn | 6.85k | 55.76 | 6.66 | 30.32 | 8.13 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 287.81bn | 5.10k | 52.78 | 9.84 | 41.65 | 8.26 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 299.51bn | 7.71k | 36.71 | 8.40 | 31.47 | 7.12 | 64.79 | 64.79 | 334.10 | 283.32 | 0.9034 | 1.30 | 3.65 | -- | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.51 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 15.18 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 77.07bn | 5.47bn | 299.71bn | 16.17k | 54.74 | 4.73 | 33.81 | 3.89 | 21.58 | 21.58 | 303.89 | 249.59 | 0.7814 | 1.22 | 5.76 | -- | 5.37 | 10.33 | 7.51 | 13.52 | 66.58 | 60.93 | 6.87 | 12.25 | 1.30 | 12.59 | 0.1569 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Gland Pharma Ltd | 56.65bn | 7.72bn | 304.12bn | 4.59k | 39.37 | 3.49 | 27.23 | 5.37 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Data as of Jun 14 2024. Currency figures normalised to Natco Pharma Ltd's reporting currency: Indian Rupee INR
12.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 7.37m | 4.12% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Apr 2024 | 3.66m | 2.04% |
| The Vanguard Group, Inc.as of 09 May 2024 | 3.37m | 1.88% |
| BlackRock Fund Advisorsas of 09 May 2024 | 1.47m | 0.82% |
| Kotak Mahindra Life Insurance Co., Ltd.as of 30 Apr 2024 | 1.38m | 0.77% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 1.38m | 0.77% |
| Jupiter Asset Management Ltd.as of 29 Feb 2024 | 961.60k | 0.54% |
| SBI Funds Management Ltd.as of 31 May 2024 | 793.23k | 0.44% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 768.12k | 0.43% |
| Causeway Capital Management LLCas of 31 Mar 2024 | 537.27k | 0.30% |
More ▼
Data from 31 Dec 2023 - 31 May 2024Source: FactSet Research Systems Inc.
